During #ASH23, Katie Maurer, MD, PhD presented Dana-Farber research that focused on #CART therapy, which found that there are features of a patient’s immune system prior to therapy that can influence the likelihood of response.
I was thrilled to present my work at the ash 2023 conference today, looking at patient baseline immunologic characteristics associated with good response to car T cell therapy. In our work, we found by single cell sequencing and flow cytometry that patients who have increased circulating B cells in their blood prior to car T therapy, as well as a higher lymphocyte to monocyte ratio have a better likelihood of good outcomes. After car T cell therapy, we also found that patients who have more CD eight T cells in their infusion products also have a better response to therapy. This is very exciting and important work because it tells us that there are features about the patients immune system prior to therapy that can influence their likelihood of response. This allows us to potentially in the future pinpoint uh patients who are most likely to benefit from car T and also to further study patients who are not having a good response to help, to find ways to make their likelihood of response to therapy better. We hope that this research will allow us to improve therapy for all patients going forward
